首页 / 产品 / 抗体 / 一抗

Rabbit Polyclonal CDK12 Antibody

  • 中文名: CDK12抗体
  • 别    名: CRK7; CRKR; CRKRS
货号: IPDX11685
Price: ¥1180
数量:
大包装询价

验证与应用

应用及物种
WB 咨询技术 Human,Mouse,Rat
IF 咨询技术 Human,Mouse,Rat
IHC 1/50-1/200 Human,Mouse,Rat
ICC 技术咨询 Human,Mouse,Rat
FCM 咨询技术 Human,Mouse,Rat
Elisa 1/5000-1/10000 Human,Mouse,Rat

产品详情

AliasesCRK7; CRKR; CRKRS
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman, Mouse, Rat
ImmunogenSynthetic peptide of human CDK12
FormulationPurified antibody in PBS with 0.05% sodium azide and 50% glycerol.

+ +

参考文献

以下为3篇涉及CDK12抗体的研究文献摘要概括:

1. **"CDK12 inhibition mediates DNA damage and cytotoxicity in human ovarian cancer cells"**

*Johnson et al.*

研究利用CDK12抗体检测卵巢癌细胞中CDK12蛋白表达,发现抑制CDK12会导致DNA损伤修复缺陷,增强化疗药物敏感性,提示其作为卵巢癌治疗靶点。

2. **"CDK12 regulates alternative polyadenylation of DNA damage response genes in prostate cancer"**

*Chen & Wang*

通过CDK12抗体进行ChIP-seq分析,揭示CDK12通过调控DNA修复相关基因的RNA多聚腺苷酸化,影响前列腺癌进展及治疗抵抗,为靶向治疗提供依据。

3. **"A pan-cancer analysis of CDK12 alterations identifies immunogenic tumors with predictive biomarker potential"**

*Zhang et al.*

利用CDK12抗体进行多癌种组织芯片分析,发现CDK12缺失或突变与肿瘤免疫微环境改变相关,提示其作为免疫治疗疗效预测标志物的潜力。

注:以上文献名为示例概括,实际研究需通过PubMed等数据库检索具体论文。CDK12抗体相关研究多聚焦于其在DNA修复、转录调控及癌症治疗中的作用机制探索。

背景信息

CDK12 (Cyclin-Dependent Kinase 12) is a serine/threonine kinase involved in transcriptional regulation, particularly in elongation and RNA processing. It plays a critical role in maintaining genomic stability by regulating the expression of DNA damage response (DDR) genes. Dysregulation of CDK12 is linked to cancers, including ovarian, prostate, and breast cancers, where its loss or mutation correlates with homologous recombination deficiency (HRD) and genomic instability. CDK12 antibodies are essential tools for studying its expression, localization, and function in both normal and pathological contexts. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess CDK12 protein levels in tissues or cell lines. Commercially available CDK12 antibodies are typically monoclonal or polyclonal, targeting specific epitopes within its kinase domain or C-terminal region. However, variability in antibody specificity has been noted, as some cross-react with homologous kinases like CDK13. Validating CDK12 antibodies using knockout controls is crucial for ensuring experimental accuracy. Recent studies highlight CDK12’s dual role in cancer progression and therapeutic resistance, making its antibodies valuable for biomarker research and targeted therapy development. Challenges remain in standardizing detection protocols due to tissue-specific expression patterns and post-translational modifications.

客户数据及评论

折叠内容

大包装询价

×